ADAPY (Adaptimmune Therapeutics) Total Assets: $130.63 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Adaptimmune Therapeutics Total Assets?

Adaptimmune Therapeutics ADAPY +5.80% Total Assets is $130.63 Mil as of Jun. 2025.

Adaptimmune Therapeutics's Total Assets for the quarter that ended in Jun. 2025 was $130.63 Mil.

Total Assets is connected with ROA %. Adaptimmune Therapeutics's annualized ROA % for the quarter that ended in Jun. 2025 was -84.07%. Total Assets is also linked to Revenue through Asset Turnover. Adaptimmune Therapeutics's Asset Turnover for the quarter that ended in Jun. 2025 was 0.09.

Adaptimmune Therapeutics  (OTCPK:ADAPY) Total Assets Explanation

Total Assets is connected with ROA %.

Adaptimmune Therapeutics's annualized ROA % for the quarter that ended in Jun. 2025 is

ROA %=Net Income (Q: Jun. 2025 )/( (Total Assets (Q: Mar. 2025 )+Total Assets (Q: Jun. 2025 ))/ count )
=-121.36/( (158.072+130.633)/ 2 )
=-121.36/144.3525
=-84.07 %

Note: The Net Income data used here is four times the quarterly (Jun. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Adaptimmune Therapeutics's Asset Turnover for the quarter that ended in Jun. 2025 is

Asset Turnover
=Revenue (Q: Jun. 2025 )/( (Total Assets (Q: Mar. 2025 )+Total Assets (Q: Jun. 2025 ))/ count )
=13.677/( (158.072+130.633)/ 2 )
=13.677/144.3525
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Adaptimmune Therapeutics Total Assets Related Terms

Adaptimmune Therapeutics Total Assets Historical Data

* Premium members only.

The historical data trend for Adaptimmune Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adaptimmune Therapeutics Total Assets Chart

Adaptimmune Therapeutics Annual Data
Trend Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 451.14 469.55 328.92 282.62 245.96

Adaptimmune Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 321.70 317.44 245.96 158.07 130.63

Adaptimmune Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Adaptimmune Therapeutics's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Assets=Total Equity (A: Dec. 2024 )+Total Liabilities (A: Dec. 2024 )
=11.849+234.114
=245.96

Adaptimmune Therapeutics's Total Assets for the quarter that ended in Jun. 2025 is calculated as

Total Assets=Total Equity (Q: Jun. 2025 )+Total Liabilities (Q: Jun. 2025 )
=-70.958+201.591
=130.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $130.63 Mil mean?
Adaptimmune Therapeutics (ADAPY) has a Total Assets of $130.63 Mil as of Jun. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Adaptimmune Therapeutics and its competitors.
Is Adaptimmune Therapeutics' Total Assets too high?
Adaptimmune Therapeutics' current Total Assets is $130.63 Mil.
How does Adaptimmune Therapeutics' Total Assets compare to BCLI and APRE?
Adaptimmune Therapeutics' Total Assets of $130.63 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Adaptimmune Therapeutics and its competitors. Adaptimmune Therapeutics's current Total Assets is $130.63 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptimmune Therapeutics stock overvalued right now?
Adaptimmune Therapeutics (ADAPY) has a current Total Assets of $130.63 Mil. The current Total Assets is $130.63 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Adaptimmune Therapeutics (ADAPY), the current Total Assets is $130.63 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adaptimmune Therapeutics Business Description

Other Exchanges 473A:Germany
Address 99 Park Drive, Milton Park, The Innovation Centre, Abingdon, Oxfordshire, GBR, OX14 4RY
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its product pipelines include ADP-600 [PRAME] and ADP-520 [CD70].